Two variants of the recently developed Vesiculovax Ebola vaccine, based on the recombinant vesicular stomatitis virus, have been tested for their ability to protect cynomolgus monkeys against challenge with the recent outbreak strain of Ebola virus. Animals received a single injection of either N4CT1 or N1CT1 Vesiculovax and were exposed to a high dose of Ebola four weeks later. None of the vaccinated animals developed illness and all survived. This raises the prospect that second-generation vaccines may have fewer side effects than the first generation currently in use.
展开▼
